Romosozumab-aqqg (Evenity™)

Evenity (romosozumab) is covered only for postmenopausal women with osteoporosis at high fracture risk (e.g., osteoporotic/fragility fracture, T‑score ≤ −2.5 or T‑score −1.0 to −2.5 with high‑risk features, or qualifying renal disease) and is limited to 210 mg SC once monthly for up to 12 doses (12‑month approval); use in men or premenopausal women is not covered. Coverage requires documentation of diagnosis, BMD/T‑scores, renal labs, and evidence of prior therapy failure, intolerance, or inability to take oral bisphosphonates (or prior IV bisphosphonate use where applicable).

"Approve 210 mg subcutaneously once every month for no more than 12 monthly doses during a therapy course."

Sign up to see full coverage criteria, indications, and limitations.